Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619040 | 0.84 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2HSD17B10MTNR1A | |
| SCHEMBL12824723 | 0.82 | HPGD (0.41) | MEN1KMT2ASMN1; SMN2HSD17B10CYP1A2 | |
| SCHEMBL18569933 | 0.82 | MEN1 (0.43) | MEN1KMT2ASMN1; SMN2HSD17B10MTNR1A | |
| SCHEMBL8438042 | 0.82 | SMN1; SMN2 (0.34) | SMN1; SMN2HSD17B10TSHR | |
| SCHEMBL10174969 | 0.80 | ALDH1A1 (0.34) | SMN1; SMN2HSD17B10RECQL | |
| SCHEMBL8964 | 0.80 | MEN1 (0.50) | MEN1KMT2ASMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL16853373 | 0.79 | MEN1 (0.40) | MEN1KMT2ASMN1; SMN2HSD17B10MTNR1A | |
| SCHEMBL12608292 | 0.79 | KDM4E (0.43) | MEN1KMT2ASMN1; SMN2HSD17B10CYP2C9 | |
| SCHEMBL26213971 | 0.79 | MEN1 (0.40) | MEN1KMT2ASMN1; SMN2HSD17B10MTNR1A | |
| SCHEMBL26789160 | 0.79 | MEN1 (0.40) | MEN1KMT2ASMN1; SMN2HSD17B10MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324221-B2 | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110053959-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053959-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, PIK3CA | MEN1 2081/4885KMT2A 3145/4885SMN1; SMN2 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.